1418TiP Randomized, placebo-controlled phase III study of 1L pembrolizumab (Pembro) plus carboplatin/taxane followed by pembro with or without maintenance olaparib in patients (Pts) with metastatic squamous non-small cell lung cancer (sqNSCLC): KEYLYNK-008

Abstract

In KEYNOTE-407, 1L pembro + carboplatin-(nab)paclitaxel (chemo) significantly improved OS in metastatic sqNSCLC. The poly(ADP-ribose) polymerase inhibitor olaparib improved outcomes as maintenance therapy vs placebo in platinum-sensitive, newly diagnosed BRCA1/BRCA2–mutated (BRCAm) ovarian cancer and relapsed/recurrent BRCAm/BRCA wild-type ovarian cancer, suggesting efficacy in tumors with homologous recombination repair deficiency (HRD) regardless of BRCAm. High HRD scores in NSCLC suggest potential benefit with olaparib maintenance in pts with NSCLC.